Aimmune Therapeutics Inc. (AIMT)

20.11
NASDAQ : Health Technology
Prev Close 20.65
Day Low/High 19.85 / 20.52
52 Wk Low/High 19.25 / 36.12
Avg Volume 591.50K
Exchange NASDAQ
Shares Outstanding 62.49M
Market Cap 1.29B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aimmune Therapeutics Announces First Quarter 2019 Financial Results And Provides Operational Highlights

Aimmune Therapeutics Announces First Quarter 2019 Financial Results And Provides Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter ended March 31, 2019.

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss First Quarter 2019 Financial Results And Recent Operational Highlights

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss First Quarter 2019 Financial Results And Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019, at 4:30 p.

Giddiness Eludes

No indicators to support giddiness as breadth improves, small caps join the party, and number of new highs looks pretty small.

Qualcomm/Apple, 'Medicare for All' Talk Ignite Extreme Market Rotation

Qualcomm/Apple, 'Medicare for All' Talk Ignite Extreme Market Rotation

There is a bloodbath of selling in medical-related names and severe pressure on cloud-related stocks that have been momentum favorites.

Aimmune Therapeutics To Present At 18th Annual Needham & Company Healthcare Conference

Aimmune Therapeutics To Present At 18th Annual Needham & Company Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

European Phase 3 Trial Of Aimmune Therapeutics' AR101 Meets Primary Endpoint

European Phase 3 Trial Of Aimmune Therapeutics' AR101 Meets Primary Endpoint

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (...

First Week Of May 17th Options Trading For Aimmune Therapeutics (AIMT)

First Week Of May 17th Options Trading For Aimmune Therapeutics (AIMT)

Investors in Aimmune Therapeutics Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

U.S. FDA Accepts BLA Filing Of Aimmune Therapeutics' AR101 For Peanut Allergy

U.S. FDA Accepts BLA Filing Of Aimmune Therapeutics' AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the Biologics License Application (BLA) for AR101 has been accepted for review by the U.

Aimmune Therapeutics To Participate In Three Investor Conferences In March

Aimmune Therapeutics To Participate In Three Investor Conferences In March

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor conferences...

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Recent Operational Highlights

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2018.

Aimmune Therapeutics Presents New AR101 Data At AAAAI, Including Demonstrated Reduction In Accidental Exposures To Peanut Requiring Treatment

Aimmune Therapeutics Presents New AR101 Data At AAAAI, Including Demonstrated Reduction In Accidental Exposures To Peanut Requiring Treatment

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented new data on AR101, its investigational treatment for peanut allergy, at the American Academy of...

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss Fourth Quarter And Full-Year 2018 Financial Results And Recent Operational Highlights

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss Fourth Quarter And Full-Year 2018 Financial Results And Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.

Trading Notes for Select Stocks

Trading Notes for Select Stocks

Here's my take on a list of stocks I've been watching.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Aimmune Therapeutics To Present AR101, OIT And Peanut Allergy Data At 2019 AAAAI Annual Meeting

Aimmune Therapeutics To Present AR101, OIT And Peanut Allergy Data At 2019 AAAAI Annual Meeting

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy, and peanut allergy at the 2019 American...

Facebook Is Today's Star as Pockets of Strong Momentum Grow

Facebook Is Today's Star as Pockets of Strong Momentum Grow

It is the action in secondary stocks that is giving the action a much better feel.

There Are a Number of Justifications For Friday's Market Strength

There Are a Number of Justifications For Friday's Market Strength

Regardless of what is moving the markets, it is a good example of how you have to focus on price action above all else.

Aimmune Therapeutics Appoints Andrew Oxtoby As Chief Commercial Officer

Aimmune Therapeutics Appoints Andrew Oxtoby As Chief Commercial Officer

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Andrew Oxtoby as Chief Commercial Officer.

Starbucks, Square, Alibaba: 'Mad Money' Lightning Round

Starbucks, Square, Alibaba: 'Mad Money' Lightning Round

Jim Cramer weighs in on Starbucks, Square, Alibaba, ArcelorMittal, Dynavax Technologies, Aimmune Therapeutics, Clearway Energy and more.

Breaking Down Citigroup Earnings: Cramer's 'Mad Money' Recap (Monday 1/14/19)

Breaking Down Citigroup Earnings: Cramer's 'Mad Money' Recap (Monday 1/14/19)

We may be so worried about the state of the global economy that we're missing some great opportunities, Jim Cramer says.

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

The stock's decline with the sector has occurred despite a steady supply of positive news.

The Market Is Transitioning Back to Stock Picking

The Market Is Transitioning Back to Stock Picking

There are obvious signs that people are trying to put cash to work.

Aimmune Therapeutics And KKR Enter Into $170M Loan Agreement To Fund AR101 Commercialization And Pipeline Advancement

Aimmune Therapeutics And KKR Enter Into $170M Loan Agreement To Fund AR101 Commercialization And Pipeline Advancement

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading global...

Aimmune Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7th

Aimmune Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7th

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas, M.

Quiet Trading Allowing Some Biotech Names to Perk Up

Quiet Trading Allowing Some Biotech Names to Perk Up

After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.

February 2019 Options Now Available For Aimmune Therapeutics (AIMT)

February 2019 Options Now Available For Aimmune Therapeutics (AIMT)

Investors in Aimmune Therapeutics Inc saw new options begin trading today, for the February 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new February 2019 contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics Submits BLA To FDA For AR101 For The Treatment Of Peanut Allergy In Children And Adolescents Ages 4-17

Aimmune Therapeutics Submits BLA To FDA For AR101 For The Treatment Of Peanut Allergy In Children And Adolescents Ages 4-17

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a Biologics License Application (BLA) to the U.